Alnylam Pharmaceuticals is a biopharmaceutical company that develops RNA-based medicines. Its filings show it lobbied Congress and federal agencies mostly on medical and disease research matters, specifically around FDA guidance for a "Platform Technology Designation Program" for drug development. It used the firm Capitol Counsel LLC and reported about $110,000 in lobbying since 2026 filings began.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
JEFFREY CARROLL
The latest disclosures for this client.
CAPITOL COUNSEL LLC
Q4CAPITOL COUNSEL LLC
Q3The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
CAPITOL COUNSEL LLC
JOHN MARTIN
CAPITOL COUNSEL LLC
CAPITOL COUNSEL LLC
Q2CAPITOL COUNSEL LLC
Q1CAPITOL COUNSEL LLC
RACAPITOL COUNSEL LLC
RR